Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2019
Metadata
Show full item recordAbstract
Adjuvant chemotherapy (AC) following pancreatic carcinoma (PC) resection improves overall survival (OS). A systematic review identified 10 phase-2/3 studies investigating AC in 3644 patients looking at the influence of nodal and resection status. AC significantly improved disease free survival, OS and 5-year odds of death risk. There was greater survival benefit in patients PS 0 and with body/tail tumors. There was a nonsignificant effect in N - ?/N? + patients on OS and no difference between R0/R1 patients.Citation
Flaum N, Hubner RA, Valle JW, Amir E, McNamara MG. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. J Surg Oncol. 2019.Journal
Journal of Surgical OncologyDOI
10.1002/jso.25440PubMed ID
30838647Additional Links
https://dx.doi.org/10.1002/jso.25440Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/jso.25440